|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300069904 |
|
最近更新日期: Date of Last Refreshed on: |
2023-03-29 10:13:13 |
|
注册时间: Date of Registration: |
2023-03-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
构建中国糖尿病共享门诊的优化试验研究(SMART) |
|
Public title: |
The Shared Medical Appointment for diabetes (SMART) in China: an optimization trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
构建中国糖尿病共享门诊的优化试验研究 |
|
Scientific title: |
Shared Medical Appointment for diabetes (SMART) in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
蔡毅媛 |
研究负责人: |
蔡毅媛 |
|
Applicant: |
Yiyuan Cai |
Study leader: |
Yiyuan Cai |
|
申请注册联系人电话: Applicant telephone: |
+86 15329009316 |
研究负责人电话:
Study leader's |
+86 15329009316 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
caiyiyuan@gmc.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
caiyiyuan@gmc.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
贵州省贵安新区大学城贵州医科大学公共卫生与健康学院 |
研究负责人通讯地址: |
贵州省贵安新区大学城贵州医科大学公共卫生与健康学院 |
|
Applicant address: |
School of Public Health and Health, Guizhou Medical University, University City, Guian New District, Guizhou Province |
Study leader's address: |
School of Public Health and Health, Guizhou Medical University, University City, Guian New District, Guizhou Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
贵州医科大学公共卫生与健康学院 |
||
|
Applicant's institution: |
School of Public Health and Health, Guizhou Medical University |
||
|
研究负责人所在单位: |
贵州医科大学公共卫生与健康学院 |
||
|
Affiliation of the Leader: |
School of Public Health and Health, Guizhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022伦审第(265)号、2022伦审第(267)号、2023伦审第 (4) 号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
贵州医科大学人体试验伦理委员会 |
||
|
Name of the ethic committee: |
Human Trial Ethics Committee of Guizhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-03-02 00:00:00 | ||
|
伦理委员会联系人: |
汤磊 |
||
|
Contact Name of the ethic committee: |
Lei Tang |
||
|
伦理委员会联系地址: |
贵州省贵安新区大学城贵州医科大学 |
||
|
Contact Address of the ethic committee: |
Guizhou Medical University, University City, Gui'an New District, Guizhou Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
贵州医科大学公共卫生与健康学院 |
||||||||||||||||||||||
|
Primary sponsor: |
School of Public Health and Health, Guizhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省贵安新区大学城贵州医科大学公共卫生与健康学院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
School of Public Health, Guizhou Medical University, University City, Guian New District, Guizhou Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金(批准号72164005) |
||||||||||||||||||||||
|
Source(s) of funding: |
The China National Natural Science Foundation (grant 72164005) |
||||||||||||||||||||||
|
研究疾病: |
糖尿病 |
||||||||||||||||||||||
|
Target disease: |
diabetes |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
析因分组(即根据危险因素或暴露因素分组) |
||||||||||||||||||||||
|
Study design: |
Factorial |
||||||||||||||||||||||
|
研究目的: |
本研究的目的是:(1)确定在中国初级保健环境中采用和实施糖尿病SMA的潜在障碍;(2)在可预见的实施障碍的条件下,确定最佳的SMA组建,实现最佳健康结果。 |
||||||||||||||||||||||
|
Objectives of Study: |
The objectives of this study are: (1) to identify the potential barriers to adopting and implementing SMA for diabetes in the primary care settings of China; (2) to identify the optimal configuration of SMA components that can potentially achieve the best health outcomes under the conditions of tackling foreseeable implementation barriers. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
医生: 参与试验的机构人员包括公卫医生和临床医生。公卫医生接受过公共卫生方面的培训,负责疾病管理,而临床医生则接受过临床培训,侧重于治疗性护理。由于实施能力的考虑,每个机构将指定一名公卫医生和一名临床医生,负责管理和提供患者的临床治疗、参与试点和优化试验。公卫医生负责糖尿病患者的健康管理。临床医生承担糖尿病患者的门诊服务工作。 |
||||||||||||||||||||||
|
Inclusion criteria |
Clinicians: Those centers typically have both public health doctors and clinical doctors. The former are usually trained in public health and are responsible for disease management, while the latter are clinically trained and focus on curative care. Each institution will designate one capable public health doctor and one clinical doctor who were responsible for managing and providing the clinical treatment for the PWD in their everyday work to participate in the pilot and optimization trials due to the implementation ability consideration. The public health doctor is taking responsibility for patients with diabetes health management. The clinical doctor takes the role of outpatient service for patients with diabetes. |
||||||||||||||||||||||
|
排除标准: |
针对医生:无排除标准 |
||||||||||||||||||||||
|
Exclusion criteria: |
Clinician: No exclusion criteria. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-04-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-04-15 00:00:00 至 To 2023-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
一名独立于SMART项目数据收集的统计人员将完成干预分配。分配给每个机构的SMA 干预包类型将遵循R软件MOST软件包(第0.1.0版)中的“随机分配生成器(Version 0.1.0)”生成的随机数字表对参与机构进行随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A statistician independent of the SMART program data collection will complete the intervention assignment. The type of SMA IP assigned to each institution will follow the random number table generated by the "Random Assignment Generator(Version 0.1.0)" in the MOST package (Version 0.1.0) of the R software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究受试患者将不设盲,研究者和数据分析员不参与随机分组过程。 |
|
Blinding: |
The participants will not be blinded. Researchers and data analysts do not participate in the randomization process. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究不分享原始数据。如果有任何特殊需要,研究者可以发送申请到 caiyiyuan@gmc.edu.cn。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
This study does not share the original data. If there are any special needs, researchers could send an application to caiyiyuan@gmc.edu.cn |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
将采用问卷星和REDCap电子方式采集数据;用REDCap管理数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Wenjuanxin and RedCap will be used for data collection and RedCap will be used for data management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |